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Pulse-chase analysis of endogenous PCSK9 secretion from HepG2 
cells. Cells were cultured in sterol-depleting medium C for 18 hours 
prior to labeling for 30 minutes with [35S]methionine/cysteine. After 
washing, cells were incubated in chase medium containing unla-
beled methionine and cysteine for the indicated times. Cells were 
lysed, and PCSK9 was immunoprecipitated from the medium and 
cell lysates as described in Methods. Samples were subjected to 
8% SDS-PAGE, and the gel was treated with Amplify fluorogenic 
reagent prior to drying and exposure to film. P and C denote the 
proprotein and cleaved forms of PCSK9, respectively. Similar results 
were obtained in 4 independent experiments.
Figure 2
Reduction of endogenous LDLRs in HepG2 cells following the 
addition of recombinant purified PCSK9 to the culture medium. (A) 
Dose response of exogenous PCSK9-mediated LDLR degrada-
tion in HepG2 cells. Cells were cultured for 18 hours in medium C 
prior to treatment for 4 hours with the indicated amounts of purified 
human PCSK9. (B) Time course of exogenous PCSK9-mediated 
LDLR degradation. HepG2 cells cultured as described above were 
treated with 5 μg/ml of purified PCSK9 for the indicated times. 
Total lysates were prepared following cell-surface biotinylation as 
described in Methods. Proteins were subjected to SDS-PAGE for 
immunoblot analysis of the LDLR using IgG-HL1 and anti–FLAG 
M2 monoclonal antibody to detect purified PCSK9. The transferrin 
receptor protein was detected as described in Methods and used 
as a control for loading and nonspecific protein degradation. Simi-
lar results were obtained in 3 independent experiments.
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The  uptake  of  PCSK9  was  characterized  morphologi-


















Increased cell association and LDLR degradation by addition of purified mutant PCSK9(D374Y) to the medium of HepG2 cells. Cells were 
cultured for 18 hours in medium C and then incubated for 4 hours with the indicated amounts of purified human PCSK9 or PCSK9(D374Y). 
Immunoblot analysis of LDLR, FLAG-tagged PCSK9, and transferrin receptor was carried out as described in the legend to Figure 2. The asterisk 
indicates a nonspecific band. Similar results were obtained in 3 independent experiments.
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LDLR-dependent endocytosis of PCSK9 in MEFs. (A) 
Immunoblot analysis of PCSK9 association with MEFs. 
Immortalized MEFs derived from wild-type, Ldlr–/–, Lrp–/–, 
and Ldlr–/–Lrp–/– mice were cultured for 18 hours in medi-
um F prior to treatment with purified human PCSK9 for 4 
hours. Cell lysates (30 μg) were subjected to SDS-PAGE 
and immunoblot analysis using IgG-15A6 to detect PCSK9 
or a polyclonal antiserum (Ab 3143) that recognizes the 
LDLR, as described in Methods. Immunoblots of receptor-
associated protein (RAP) were used as a loading control. 
(B) Indirect immunofluorescence localization of PCSK9 
and the LDLR in wild-type MEFs. MEFs were incubated 
for 4 hours with 5 μg/ml purified human PCSK9 and pro-
cessed for double immunofluorescence of PCSK9 (green) 
and the LDLR (red) as described in Methods. (C) Indirect 
immunofluorescence localization of PCSK9, LDLR, and 
the late-endosomal marker CI-MPR in MEFs cultured in 
the presence of chloroquine. Wild-type MEFs were incu-
bated for 4 hours with 5 μg/ml purified human PCSK9 in 
the presence of 0.1 mM chloroquine and processed for 
double immunofluorescence of PCSK9 (green) and the 
LDLR (red) or CI-MPR (red) as described in Methods. The 
merged image shows areas of colocalization of PCSK9 with 
the LDLR and CI-MPR. Magnification, ×630. Similar results 
were obtained in 3 independent experiments.
Downloaded on June 19, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/29383
research article























































Although  an  apoE  promoter  fragment  and  a  liver-specific 
enhancer were used to express the human PCSK9 cDNA in mice, 
Figure 5
Association of PCSK9 and PCSK9(D374Y) with the LDLR. (A) 
Coimmunoprecipitation of the LDLR and exogenously added 
wild-type PCSK9 or PCSK9(D374Y) protein. HepG2 cells were 
cultured for 18 hours in medium C prior to treatment for 1 hour in 
the presence of 0.1 mM chloroquine with 20 μg/ml or 2 μg/ml of 
purified human PCSK9 or PCSK9(D374Y), respectively. Cells 
were harvested and lysed and proteins immunoprecipitated 
with the indicated antibodies. Pellets of the immunoprecipitation 
were subjected to SDS-PAGE and immunoblot analysis. 
Polyclonal antiserum (Ab 3143) was used to detect LDLR, 
and IgG-15A6 was used to detect PCSK9. (B) Reduced (R) 
or nonreduced (NR) LDLR extracellular domain protein (2 μg) 
was resolved by SDS-PAGE. LDLR protein was detected with 
Coomassie brilliant blue R-250 stain. (C) Binding of PCSK9 to 
LDLR on ligand blots. LDLR protein (2 μg) was transferred to 
nitrocellulose and incubated with 5 μg/ml of purified PCSK9 or 
no addition (NA). Bound PCSK9 was detected by immunoblot 
analysis as described in Methods. (D) The indicated amounts 
of purified LDLR were subjected to nonreduced SDS-PAGE, 
transferred to nitrocellulose, and incubated with 5 μg/ml of puri-
fied wild-type PCSK9, PCSK9(D374Y), or buffer control (no 
addition). Bound PCSK9 was detected by immunoblot analysis 
as described in Methods. pep., FLAG octapeptide.
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PCSK9-mediated degradation of the LDLR is 
dependent on ARH. Immunofluorescence (A) and 
immunoblot (B) analyses of the PCSK9-medi-
ated changes of LDLR protein in mouse primary 
hepatocytes derived from LDLRh/hArh+/+ (Arh+/+) or 
LDLRh/hArh–/– (Arh–/–) mice. (A) Primary hepatocytes 
were incubated with no PCSK9 (–PCSK9) or with 
5 μg/ml purified PCSK9 (+PCSK9) for 4 hours and 
processed for indirect immunofluorescence of LDLR 
using IgG-C7 and Alexa Fluor 563–conjugated sec-
ondary antibody, as described in Methods. Images 
were taken using a 63 × 1.3 objective using a con-
focal microscope (Leica TCS SP). Similar results 
were obtained in 2 independent experiments. (B) 
Immunoblot analysis of LDLR, FLAG-tagged PCSK9, 
transferrin receptor, and actin proteins in primary 
hepatocytes from mice of the indicated genotype 
incubated with varying amounts of PCSK9.
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which showed  that LDLRs were  required  for  the major-
ity of PCSK9 to associate with the cell surface (Figure 4A 























Total plasma cholesterol and PCSK9 concentrations in pre- and post-
parabiotic pairs of wild-type, Ldlr–/–, and TgPCSK9 (Tg) mice
Parabiotic  Genotype Before parabiosis After parabiosis
pair  Cholesterol Cholesterol hPCSK9
  (mg/dl) (mg/dl) (μg/ml)
1a WT 54 79 0
1b WT 60 85 0
2a WT 67 91 0
2b WT 67 60 0
3a WT 54 85 0
3b WT 42 63 0
4a WT 51 81 0
4b WT 60 71 0
5a Ldlr–/– 178 288 0
5b WT 56 76 0
6a Ldlr–/– 182 270 0
6b WT 57 64 0
7a Ldlr–/– 175 278 0
7b WT 53 82 0
8a Ldlr–/– 179 145 0
8b WT 68 101 0
9a Tg 142 365 440
9b WT 70 775 246
10a Tg 132 350 198
10b WT 66 364 148
11a Tg 180 278 146
11b WT 61 233 80
12a Tg 140 171 184
12b WT 61 131 17
Figure 7
Decreased amounts of hepatic LDLR protein and increased levels of 
plasma LDL cholesterol in transgenic PCSK9 mice. (A) Whole-cell 
lysates (30 μg) from livers of 5 wild-type and 5 TgPCSK9 mice were 
subjected to SDS-PAGE and immunoblot analyses of human PCSK9, 
mouse LDLR, and mouse ARH. (B) Plasma from the mice of each 
genotype described in A and from 5 age-matched male Ldlr–/– mice 
was pooled and subjected to gel filtration by fast performance liquid 
chromatography. The concentration of total cholesterol in each fraction 
was measured as described in Methods.
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Amounts of LDLR protein in livers of parabiosed 
mice. Three combinations of mice were parabiosed 
for study: wild-type:wild-type (A); Ldlr–/–:wild-type 
(B); and TgPCSK9:wild-type (C). Prior to parabiosis, 
a liver sample (<100 mg) via a partial hepatectomy 
and approximately 50 μl of blood via the tail vein were 
obtained from each mouse. After a 7-day recovery 
period, 12- to 20-week-old female mice of the indicat-
ed genotype were parabiosed as described in Meth-
ods. After 2 weeks of parabiosis, the animals were 
killed, and blood and liver samples were collected for 
analysis. Liver membrane protein (40 μg) obtained 
from each mouse before (–) and after (+) parabiosis 
was subjected to SDS-PAGE for immunoblot analy-
ses of LDLR and RAP as a loading control (9).
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Pulse-chase analysis of PCSK9. HepG2 cells were cultured in medium C, 
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